GLTO (Galecto Inc) רווח למניה בארבעת הרבעונים האחרונים

Galecto, Inc. generates revenue by developing oncology and fibrosis treatments, planning to derive profit from the licensing of specific inhibitors. The annual EPS TTM trend captures a turning point driven by the scientific recognition of anti-inflammatory methods and streamlined raw material logistics. The current level of 37.40 serves as a critical benchmark determining the current fundamental value of the company's shares.

For the biotechnology company Galecto, Inc. (GLTO), this indicator serves as a measure of the efficiency of intellectual capital monetization. The metric calculates the percentage change in earnings per share over the last four quarters relative to the same period last year. By analyzing the 12-month EPS annual growth trend, an investor assesses the speed of business scaling. The stability of R&D personnel and the retention of fibrosis experts create the foundation for the long-term growth of this figure. High values signal market optimism but increase the sensitivity of quotes to any deviations from forecasts.